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Behavioral/Systems/Cognitive
Increased Expression of the 5-HTTransporter Confers a Low-
Anxiety Phenotype Linked toDecreased 5-HTTransmission
Katie A. Jennings,1Merewyn K. Loder,2W. John Sheward,2 Qi Pei,1 Robert M. J. Deacon,3Matthew A. Benson,1
Henry J. Olverman,2Nicholas D. Hastie,4 Anthony J. Harmar,2 Sanbing Shen,2 and Trevor Sharp1
1Department of Pharmacology, Oxford University, Oxford OX1 3QT, United Kingdom, 2Centre for Neuroscience Research, School of Biomedical Sciences,
University of Edinburgh, Edinburgh EH8 9JZ, United Kingdom, 3Department of Experimental Psychology, Oxford University, Oxford OX1 3UD, United
Kingdom, and 4Medical Research Council Human Genetics Unit, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
A commonly occurring polymorphic variant of the human 5-hydroxytryptamine (5-HT) transporter (5-HTT) gene that increases 5-HTT
expression has been associated with reduced anxiety levels in human volunteer and patient populations. However, it is not known
whether this linkage between genotype and anxiety relates to variation in 5-HTT expression and consequent changes in 5-HT transmis-
sion. Here we test this hypothesis by measuring the neurochemical and behavioral characteristics of a mouse genetically engineered to
overexpress the 5-HTT. Transgenic mice overexpressing the human 5-HTT (h5-HTT) were produced from a 500 kb yeast artificial
chromosome construct. These transgenic mice showed the presence of h5-HTTmRNA in themidbrain raphe nuclei, as well as a twofold
to threefold increase in5-HTTbinding sites in the raphenuclei anda rangeof forebrain regions.The transgenicmicehad reduced regional
brain whole-tissue levels of 5-HT and, in microdialysis experiments, decreased brain extracellular 5-HT, which reversed on administra-
tion of the 5-HTT inhibitor paroxetine. Compared with wild-type mice, the transgenic mice exhibited a low-anxiety phenotype in plus
maze and hyponeophagia tests. Furthermore, in the plus maze test, the low-anxiety phenotype of the transgenic mice was reversed by
acute administration of paroxetine, suggesting a direct link between the behavior, 5-HTT overexpression, and low extracellular 5-HT. In
toto, these findings demonstrate that associations between increased 5-HTT expression and anxiety can bemodeled inmice andmay be
specifically mediated by decreases in 5-HT transmission.
Key words: serotonin; serotonin transporter; anxiety; polymorphism; microdialysis; serotonergic
Introduction
Brain 5-hydroxytryptamine (5-HT; serotonin) neuronal path-
ways are strongly implicated in the pathophysiology of a number
of common and severe psychiatric disorders, and biological vari-
ation in 5-HT neurotransmission is likely to be a major psychiat-
ric disorder risk factor. Reuptake of 5-HT by the 5-HT trans-
porter (5-HTT; SERT) is a key control point in 5-HT
neurotransmission because it is themain route by which released
5-HT is cleared from the synapse (Blakely et al., 1994; Lesch and
Gutknecht, 2005). The human 5-HTT gene has a number of com-
monly occurring polymorphisms that may be a source of varia-
tion in 5-HTT expression in the human population (Heils et al.,
1996; Ogilvie et al., 1996; Heinz et al., 2000; Kilic et al., 2003;
Ozaki et al., 2003).
Of special interest are two alleles, the short (s) and long (l), in
a repetitive element of varying length (5-HTTLPR) in a promoter
region of the 5-HTT gene (44 bp insertion/deletion) that alters
5-HTT gene transcription and expression. Cultured cells express-
ing two copies of the l allele exhibit an increase in 5-HTTmRNA
and a twofold increase in 5-HT uptake compared with cells ex-
pressing either one or two copies of the s allele (Lesch et al., 1993).
Moreover, it is reported that individuals with the l/l genotype
have increased 5-HT uptake, 5-HTT binding sites, andmRNA in
brain and platelets compared with individuals with the s/s and s/l
genotypes, in postmortem as well as neuroimaging studies
(Hanna et al., 1998; Little et al., 1998; Greenberg et al., 1999;
Heinz et al., 2000). Also, there is up to a twofold to threefold
difference in the number of brain 5-HTT binding sites from one
healthy individual to the next (Malison et al., 1998; Mann et al.,
2000), and this variationmay be genetically driven, at least in part
through polymorphisms in the 5-HTT gene promoter region.
Recent gene linkage studies find that l/l allele carriers have
decreased anxiety-related traits compared with carriers of the s/l
and s/s alleles. Thus, l/l allele carriers exhibited decreased neurot-
icism scores (Lesch et al., 1996; Greenberg et al., 2000) and
showed reduced anxiety-related responses to fearful stimuli com-
paredwith carriers of the s allele (Hariri et al., 2002; Pezawas et al.,
2005). It is reasonable to assume that these gene associations are
linked to altered 5-HTT expression because there are well estab-
lished and strong connections between 5-HT and anxiety
(Griebel, 1995; Handley, 1995), and mice with null mutations of
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the 5-HTT gene are anxious in anxiety paradigms (Holmes et al.,
2003a,b). However, this linkage is not proven because the latter
mouse does not model the level of natural variation in 5-HTT
expression that likely occurs among individuals with different
5-HTT genotypes.
Recently, we reported preliminary accounts of a novel mouse
genetically engineered to overexpress the human 5-HTT (Loder
et al., 2000; Jennings et al., 2003). Here we examine the neuro-
chemical and behavioral characteristics of this transgenic mouse




Experiments were conducted in accordance with the United Kingdom
Animals (Scientific Procedures) Act of 1986. Male mice (CBAC57BL/
6J; 3–6 months of age; heterozygote transgenic mice and wild-type lit-
termates) were generated as described below. Mice were group housed
(unless stated otherwise) on a 12 h light/dark cycle (lights off 8:00 P.M. to
8:00 A.M.) in a temperature-controlled environment (21 1°C). Behav-
ioral testing was performed during the first 6 h of the light phase of the
light/dark cycle.
Generation of 5-HTT-overexpressing mice
The 500 kb yeast artificial chromosome (YAC) 35D8 consisted of the
human 5-HTT (h5-HTT) gene flanked by 150 kb of 5 and 300 kb of 3
sequences with the “short” allele of the 5-HTTLPR in the promoter re-
gion and the 10-repeat allele of the variable number tandem repeat in
intron 2 (Shen et al., 2000a). This YAC was modified by homologous
recombination to include a hemagglutinin (HA) epitope tag at the C
terminus of the h5-HTT protein and a lacZ reporter gene downstream of
an internal ribosomal entry site using placZSERT and pYAM4 (Shen et
al., 2000b). The vector placZSERT was constructed by inserting (1) a
fragment of h5-HTT genomic DNA extending 5 kb upstream from the
stop codon (obtained by PCR using forward primer 5-ACTGCAT-
AGCGGCCGCATCTTTCATTTGCATCCCC-3 and reverse primer 5-
TGTGCTCGAGAGCATTCAAGCGGATGT-3) into the NotI–XhoI
sites of pYIV3 and (2) the sequence downstream of the stop codon (ob-
tained by PCR with forward primer 5-CTCCTCGAGAGGAAAAA-
GGCTTCT-3 and reverse primer 5-TAGGTACCCTGTTCTCTCCTA-
CGCAGTTT-3) into the SalI–KpnI sites of pYIV3. The unmodified and
placZSERT-modified YAC 35D8 were then transformed with NotI-
linearized pYAM4 to amplify YAC DNA.
YACDNAwas purified by pulsed field gel electrophoresis as described
by Schedl et al. (1996) and injected into the fertilized eggs (CBA 
C57BL/6J). Transgenic mice were identified by PCR using primer pairs
for h5-HTT (exon 1A, exon 1B, intron 1A, and 3 untranslated region),
sequence tag site markers (D17S2009, D17S2004, D1S1294, and
D17S1549), and the YAC vector arms (Shen et al., 2000a). The transgene
copy number was determined using densitometric measurement (NIH
Image) of the ratios of the 2.6 kb h5-HTT over the 3.8 kb mouse 5-HTT
(m5-HTT) genomic DNA, which were amplified by PCR with primers
E4F (5-CTACCTCATCTCCTCCTTCACG-3) and E7R (5-TTGTT-
GTTGAACTTGTTGTAGC-3) in the exponential phase (15–23 cycles).
Reverse transcription-PCR
RNAwas extracted from the cortex and brainstem of the transgenicmice
and littermate controls usingRNAzol B (Biogenesis, Bournemouth,UK),
and cDNA was synthesized with Omniscript kits (Qiagen, Chatsworth,
CA). Bothm5-HTTandh5-HTTcDNAwere amplifiedwith primers E4F
and E7R. Digestion of the 513 bp reverse transcription (RT)-PCR prod-
ucts withHpaII produced a 461 bp fragment fromm5-HTT and a 295 bp
fragment from h5-HTT. Digestion with HinfI resulted in a 513 bp frag-
ment from the h5-HTT and fragments of 177 bp and a 249 bp from the
m5-HTT. Digested DNA products were separated on 5%nondenaturing
acrylamide or 2% agarose gels. In some experiments, the PCR primers
were 32P labeled using T4 polynucleotide kinase, and restriction frag-
ments of PCR products were detected by autoradiography of dried gels
using Eastman Kodak (Rochester, NY) Biomax film.
Western blotting
Tissue was examined for the presence of the HA-tagged epitope using
Western blotting. Protein extracts were prepared by homogenizing fresh
lung tissue in treatment buffer (4 M urea, 3.8% SDS, 20% glycerol, 75mM
Tris, pH 6.8, and 50mMDTT). Extracted protein (300g) and a positive
control (HA-tagged ubiquilin) were separated on 10% SDS-
polacrylamide gels and transferred to nitrocellulosemembranes in trans-
fer buffer (20% methanol, 0.1% SDS, 192 mM glycine, and 25 mM Tris-
HCl, pH 8.5) for 60 min at 75 V. Membranes were blocked in 5% milk
powder in Tris-buffered saline with Tween (TBST; 150 mMNaCl, 50 mM
Tris-HCl, pH 7.5, and 0.1% Tween 20) for 1 h. Primary (chicken anti-
HA, AB 3254; Chemicon, Temecula, CA) and secondary (HRP-
conjugated anti-chicken; The Jackson Laboratory, Bar Harbor, ME) an-
tibodies were applied in 5% milk powder in TBST at concentrations of
1:1000 and 1:5000, respectively, for 1 h each. Themembrane was washed
three times for 5 min in 5% milk powder in TBST after application of
each antibody. Antibodies were visualized using Pierce (Rockford, IL)
ECL Western blotting substrate.
Measurement of 5-HTT mRNA using in situ hybridization
Mice (five to six per group) were killed by cervical dislocation, brains
were snap-frozen in isopentane/solid CO2, and coronal sections (12m)
were cut on amicrotome cryostat (20°C), collected onto gelatin-coated
slides, and stored at70°C.
Oligonucleotide probes included a 40-mer m5-HTT-specific probe
(5-CGTGTCACCAGCTAATGTGGCAGTAAGTCCAAGAGAGTTC-
3; Sigma-Genosys, The Woodlands, TX) and a 42-mer h5-HTT probe
(5-CACCCAGCAGATCCTCCAgAACCAcCCcGGGCTGAAGCCgAG-
3) with four mismatches to the m5-HTT (indicated in lowercase). The
probes (1 pmol/l) were end labeled with [ 35S]dATP (12.5 mCi/ml;
NEN Life Science Products, Boston, MA) by incubation at 37°C for 30
min with terminal deoxynucleotidyl transferase (Promega, Madison,
WI), purified through Sephadex G-50, and diluted to 1.2 106 cpm/100
l in hybridization buffer containing 50% formamide, 2 or 4 SSC,
and 0.05 mM DTT. Each slide was loaded with a 100 l probe, covered
with a glass coverslip, and placed in lidded incubation trays containing
filter paper soaked in 50 ml of 50% formamide in 4 SSC. Sections were
hybridized overnight in 50% formamide with 4 SSC at 34°C (m5-HTT
probe, high stringency), 50% formamide with 2 SSC at 37°C (h5-HTT
probe, high stringency), or 50% formamide with 4 SSC at 33°C (low
stringency to detect both m5-HTT and h5-HTT mRNA). Hybridized
sections were washed in 1 SSC at 55°C three times for 20 min and at
room temperature two times for 1 h. Slides were rinsed in water, dried,
and exposed to Betamax film (Amersham Biosciences, Buckingham-
shire, UK) for 4 weeks.
The abundance of mRNA in selected areas was determined by densi-
tometric quantification of autoradiograms (MCID, St. Catherines, On-
tario, Canada). Optical density values were calibrated to [ 35S] tissue
equivalents using [ 14C] microscales (Amersham Biosciences) as de-
scribed previously (Pei et al., 2003). Densitometric valuesmeasured from
three sections of each animal were averaged and expressed as nanocurie
per gram of tissue.
Measurement of 5-HTT binding sites
Membrane binding assay. 5-HTT binding sites in tissue membranes were
assayed using standard radioligandbindingmethodology (Marston et al.,
1999). In brief, the cerebral cortex from transgenic mice and littermate
controls was homogenized in 50 vol (w/v) of ice-cold 50 mM Tris-HCl
buffer, pH 7.4, and centrifuged (30,000  g, 10 min). The membrane
pellet was resuspended in 50 mM Tris-HCl and incubated at 25°C for 10
min, and membranes were washed by centrifugation (30,000  g, two
times for 10 min). The final membrane pellet was resuspended in 20 vol
of buffer and stored (20°C). On the assay day, membranes were sus-
pended in 200 vol of 50 mM Tris-HCl buffer (120 mM NaCl and 5 mM
KCl, pH 7.4), and binding of 0.25 nM [3H]citalopram (specific activity,
83 Ci/mmol; NEN Life Science Products) was measured in duplicate in
the absence or presence of unlabeled citalopram (0.001–100 nM).
Nonspecific binding was defined using 1 M paroxetine. Samples were
incubated for 1 h at 25°C, binding was terminated by filtration, and
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radioactivity wasmeasured by scintillation counting. Data were analyzed
using iterative, nonlinear least-squares curve fitting to provide binding-
site affinity (KD) and density (Bmax) values (Prism;GraphPad, SanDiego,
CA) and tested statistically using Student’s unpaired t test.
Receptor autoradiography. Brains from six heterozygous transgenic
males and five wild-type littermates (age, 3–6 months) were removed,
frozen in an isopentane bath at 30°C, and stored at 70°C before
sectioning. Coronal sections (12 m) were cut using a microtome cryo-
stat (20°C), mounted on gelatin-coated slides, and stored at 70°C.
Slides were subsequently thawed and preincubated in 50 mM Tris-HCl
buffer (120 mM NaCl and 5 mM KCl, pH 7.4) for 15 min, before incuba-
tion in 50 mM Tris-HCl buffer containing 2 nM [3H]citalopram for 60
min. Nonspecific binding was defined by 1 M imipramine. Sections
were washed in ice-cold Tris-HCl buffer (two times for 10 min) and
rinsed in ice-cold distilled water before drying in a cold air stream.
Slides were exposed to [ 3H]-sensitive Hyperfilm (Amersham Bio-
sciences) at 4°C for 6 weeks. The relative abundance of 5-HTT binding
sites was determined by densitometric quantification of autoradiograms,
calibrated to tritiated tissue equivalents (Amersham Biosciences), and
corrected for nonspecific signals. Optical densities from three sections
per animal were averaged and expressed as femtomoles per milligram of
tissue. Data were analyzed statistically on a region-by-region basis using
Student’s unpaired t test. In addition, regional binding was compared
across genotypes using a correlation analysis (Pearson’s).
Measurement of whole-tissue 5-HT and other analytes
Mice (10 per group) were either treatment naive or administered the
aromatic amino acid decarboxylase inhibitorNSD 1015 (100mg/kg, i.p.)
30 min before they were killed. Brains were removed, and regions (in-
cluding the frontal cortex, striatum, and hippocampus) were rapidly
dissected out on ice and frozen in isopentane (20°C) and stored at
70°C.
On the day of analysis, samples were homogenized in 1 ml of 0.1 M
perchloric acid and centrifuged (15,000 g, 15 min). Supernatants were
stored on ice before analysis using HPLC with electrochemical detection
(see below). Data were converted into picomoles per milligram of wet
weight, and comparisons between genotype were made on a region-by-
region basis using Student’s unpaired t test.
Microdialysis
Microdialysis experiments were performed using anesthetized mice be-
cause of technical difficulties perfusing and administering drugs to freely
moving mice. Previous studies in rats found similar effects of 5-HTT
inhibitors under awake and anesthetized conditions (Gartside et al.,
1995; Castro et al., 2003).
Mice (five to six per group) were anesthetized (chloral hydrate; 500
mg/kg, i.p., 50–100 mg/kg/h thereafter), and single cannula microdialy-
sis probes were stereotaxically implanted into either the medial prefron-
tal cortex [rostrocaudal, lateral, and dorsoventral coordinates1.9 mm,
0.4 mm, and2.0 mm, respectively, relative to bregma and dura sur-
face (Franklin and Paxinos, 1997)] or the hippocampus (coordinates:
1.1 mm, 1.5 mm, 3.6 mm). Probes were perfused continuously
with artificial CSF (in mM: 140 NaCl, 3 KCl, 1.2 Na2HPO4, 0.27
NaH2PO4, 1 MgCl2, 2.4 CaCl2, and 7.2 glucose) at a rate of 2 l/min.
After a 1.5 h postimplantation period, baseline dialysates (20 min
samples) were collected for 2 h before switching to CSF containing high
potassium (56 mM KCl and 87 mM NaCl) for 20 min, followed by perfu-
sion with normal CSF for an additional 1 h. In another set of experi-
ments, after the 2 h baseline period, either the perfusion medium was
switched to CSF containing 1 M paroxetine or 5 mg/kg paroxetine was
injected intraperitoneally. At the end of each experiment, brains were
removed to confirm correct probe placement by histological analysis.
Under the above conditions, 5-HT levels were stable after the 2 h baseline
period, and removal of calcium from the perfusion medium reduced
5-HT levels by 70–80% (n 5).
Microdialysis data were analyzed either as raw data (picomoles per 40
l dialysate) or percentage of baseline, using the last time point before
treatment as 100%. Genotypes were compared using one- or two-way
repeated-measures ANOVA as appropriate, and post hoc testing was by a
Bonferroni’s t test.
HPLC analysis
Dialysates and tissue supernatants were assayed for 5-HT and other ana-
lytes (dopamine, noradrenaline, 5-HIAA, 5-HTP, DOPAC, DOPA) us-
ing HPLC with electrochemical detection. Analytes were separated on
Microsorb C18 reverse-phase columns (4.6  100–150 mm) and de-
tected (LC-4B electrochemical detector) using a glassy carbon working
electrode (0.7 V vs silver/silver chloride). The mobile-phase composi-
tions (flow rate, 1ml/min) for separation of the different analytes were as
follows: 5-HT, 5-HIAA, and DOPAC: 12.5%methanol, 0.1 M NaH2PO4,
0.8 mM EDTA, and 0.01 mM sodium octane sulfonate, pH 3.55; 5-HTP
and DOPA: 12%methanol, 0.1 M NaH2PO4, 0.8 mM EDTA, and 1.7 mM
sodium octane sulfonate, pH 3.8; noradrenaline and dopamine: 14.5%
methanol, 0.1 M NaH2PO4, 0.8 mM EDTA, and 3.2 mM sodium octane
sulfonate, pH 3.35.
Behavioral testing
Plus maze. The plus maze apparatus was elevated 50 cm and comprised
open (29 4 cm, 0.5 cmwalls) and closed (27 8 cm, 30 cmwalls) arms
joined by a central open space (8 4 cm). Transgenic andwild-typemice
(eight per group) were placed at the distal end of a closed arm, and the
amount of time spent in the open arms, the number of entries into the
open arms, the total number of arm entries, and the latency to first enter
the open arm were measured. Testing was videotaped in the absence of
the investigator, with the apparatus lit by a 60W light bulb directed away
from the apparatus. In separate experiments, mice (four groups of eight)
were administered paroxetine (10 mg/kg, i.p.) or saline vehicle 30 min
before testing.
Hyponeophagia. Food consumption of singly housed mice was moni-
tored over a 16 h period (including overnight) and restricted to one-third
of this amount the night before testing. The following day, mice (eight
per group) were placed singly in a transparent plastic box (26 16 17
cm) with the floor covered with an even layer of food pellets (Noyes,
Lancaster, NH). This method ensures that the mouse is immediately
aware of the food and sensorimotor factors do not confound the anxiety
measurement. Latency to begin feeding was defined as the time taken for
amouse to hold a pellet in the forepaws and eat continuously (at least 3 s).
Open-field test. The open-field test was performed as described previ-
ously (Deacon et al., 2002) using an open-topped rectangular box (50
30  30 cm) constructed from gray plastic with the floor divided into
15 10 cm squares, under low-light conditions. Mice (eight per group)
were placed individually in a corner square, and the number of squares
entered in a 3 min period was measured.
Behavioral data were analyzed statistically using either Student’s un-
paired t test or two-way ANOVA followed by a post hoc Bonferroni’s test,
as appropriate. All cases of significance detected using Student’s t test
were confirmed using the Mann–Whitney U test.
Results
Generation of 5-HTT-overexpressing mice
The successful integration of the YAC DNA into transgenic lines
and its integritywere verified by the presence of the PCRproducts
of primer pairs a–j (Fig. 1A and data not shown). Transgene copy
numbers were estimated from the ratios of PCR products of h5-
HTT (2.6 kb) and m5-HTT (3.8 kb) genomic DNA in the expo-
nential phase of amplification, using primers E4F and E7R (Fig.
1B). The transgenic mouse lines A102.3 (eight copies) and A104
(three copies) made with the modified YAC contained all mark-
ers examined, and line A145.1 (five copies) made with unmodi-
fied YAC DNA lacked the short vector arm only.
Expression of the h5-HTT in transgenic mice
To examine h5-HTT expression, total RNA was extracted from
the cortex and brainstem (including midbrain raphe nuclei) of
wild-type and transgenic mice and analyzed by RT-PCR for both
m5-HTT and h5-HTT cDNA (Fig. 1C). m5-HTTwas detected in
the brainstem (Fig. 1D,E, lane 5) but not in the cortex (Fig. 1D,E,
lane 1) of wild-type controls. Expression of the h5-HTT was de-
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tected in both the brainstem (Fig. 1D,E, lanes 6–8) and cortex
(Fig. 1D,E, lanes 2–4) of all transgenic lines (Fig. 1D,E). The
three transgenic lines (A102.3, A104, and A145.1) overexpressed
comparable levels of the h5-HTT mRNA. The A102.3 line of
transgenic mice was selected for investigation in more detail.
Immunocytochemical studies of brain tissue failed to detect
specific staining of -galactosidase or of the HA tag using a num-
ber of commercial antibodies or (in the case of -galactosidase)
by X-Gal staining. This may indicate that the level of expression
of the human SERT protein was too low to be detectable by
immunocytochemistry. In addition, LacZ transgenes often func-
tion poorly in adult animals (Cohen-Tannoudji et al., 2000).
In another attempt to verify expression of the HA epitope in
the transgenic animals, additional Western blotting experiments
were performed on lung tissue. This tissue has a higher level of
5-HTT expression than brain (Ramamoorthy et al., 1993), which
is further enhanced in the transgenicmice (MacLean et al., 2004),
thereby making the HA epitope easier to detect. Indeed, lung
tissue from the transgenic mice showed a distinct HA-
immunolabeled band at the molecular weight predicted for the
5-HTT (70 kDa), that was absent in the wild-type controls
(Fig. 1F).
Localization of 5-HTTmRNA in transgenic mice
The brain localization of 5-HTT transgene was investigated (n
6 transgenic and wild-type mice) by in situ hybridization with a
m5-HTT-specific probe under high-stringency conditions that
detected m5-HTT transcripts only (Fig. 2A,F) and with a h5-
HTT probe under high-stringency conditions that detected h5-
HTT RNA only (data not shown), or under less stringent condi-
tions that detected both m5-HTT and h5-HTT RNA (Fig.
2B–E,G–J).
In wild-type controls, m5-HTT was found predominantly in
the dorsal raphe nucleus (Fig. 2F–G)with lower abundance in the
median raphe and ventrolateral dorsal raphe nuclei, consistent
with the expression pattern reported previously (Bengel et al.,
1997). There was no detectable m5-HTT expression in any other
brain region examined (Fig. 2H–J). The transgenic mice ex-
pressed the h5-HTT in a pattern similar to the endogenous
5-HTT with predominant hybridization signals observed in the
raphe nuclei (Fig. 2B).
Total 5-HTT mRNA was increased 2.9-fold in the dorsal ra-
phe nucleus (2578 266 vs 890 71 nCi/g tissue for transgenic
and wild-type mice, respectively), 1.8-fold in the median raphe
nucleus (938  164 vs 521  37 nCi/g tissue), and 2-fold in the
ventrolateral dorsal raphe nucleus (1118 161 vs 539 60 nCi/g
tissue). These differences were statistically significant ( p 0.05).
The increase was attributable to expression of the transgene, be-
4
right) were for the long YAC vector arm (a), D17S2004 (b), D17S2009 (c), h5-HTT promoter (d),
intron 1A (e), intron 1B (f), 3 untranslated region (g), D17S1294 (h), D17S1549 (i), and the
short armof the YAC vector (j).B, PCR amplification of a 2.6 kb genomic DNA fragment from the
human 5-HTT gene and a 3.8 kb fragment from the m5-HTT gene using primers E4F and E7R.
Thesedatawereused toestimate the transgene copynumber.C, Expressionof 5-HTTmRNAwas
determined by RT-PCR with primer pairs E4F and E7R and by subsequent restriction digestion.
D, An autoradiogram of PCR products obtained using 32P-labeled primers and digested with
HpaII. E, Restriction fragments of PCR products obtained using unlabeled primers and detected
by ethidiumbromide staining. RNA templateswere from the cortex (lanes 1–4) and brainstem
(lanes 5–8) ofwild-type (lanes 1, 5), A102.3 (lanes 2, 6), A145.1 (lanes 3, 7), and A104 (lanes 4,
8) transgenic mice. F, Western blot demonstrating the presence a HA-tagged epitope in lung
tissue from transgenic (A102.3) but not wild-type mice. The positive control lane (HA) repre-
sents HA-tagged ubiquilin. Wt, Wild type.
Figure 1. Creation and characterization of transgenic mice expressing the h5-HTT. Three
lines of transgenic mice were generated (lines A145.1, A102.3, and A104). A, Open circles
indicate the presence of markers in each transgenic line. The primer pairs used (from left to
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cause the h5-HTT probe displayed weaker hybridization signals
in the wild-type mice (Fig. 2G) than in transgenic mice (Fig. 2B)
and the m5-HTT-specific probe showed similar levels and pat-
tern of m5-HTT RNA expression in transgenic (Fig. 2A) and
wild-type (Fig. 2F) mice.
In addition to overexpression in the raphe nuclei, the trans-
genic mice also showed low levels (6 –8% of that in the raphe)
of h5-HTT expression outside the brainstem, including the
CA1–CA3 regions and dentate gyrus of the hippocampus (Fig.
2C), the piriform cortex (Fig. 2E, arrow), and the granular cell
layer of the olfactory bulb (Fig. 2D, arrow). No endogenous
m5-HTT was detected in these regions of the wild-type con-
trols (Fig. 2H–J ).
5-HTT binding sites in transgenic mice
5-HTT binding was analyzed using a membrane binding assay
and receptor autoradiography, performed at equilibrium condi-
tions with [3H]citalopram. In the membrane binding assay,
transgenic mice and wild-type controls showed similarKD values
for [3H]citalopram (1.75 0.14 vs 1.29 0.21 nM, respectively)
with Hill coefficients close to unity (0.89  0.11 vs 1.03  0.08,
respectively). Transgenic mice, however, displayed a significant
(3.2-fold) increase ( p  0.01) in the density of [3H]citalopram
binding sites in cortical tissue compared with wild-type controls
(2800 625 vs 862 312 fmol/mg protein, respectively).
Autoradiograms revealed a distribution of [3H]citalopram
binding sites (Fig. 3A,B) in wild-type mice similar to that re-
ported in previous studies (Le Marec et al., 1998). The density of
[3H]citalopram binding sites was greater in the transgenic mice
compared with the wild-type controls. The increase in [3H]cita-
loprambinding sites ranged from3.3-fold in cortical regions to
1.5- to 1.8-fold in the thalamus and hippocampus (Fig. 3B). The
regional pattern of [3H]citalopram binding sites in transgenic
mice was similar to wild-type controls (Fig. 3A,B). Thus, in both
transgenic and wild-type mice, [3H]citalopram binding sites
were most abundant in the dorsal and median raphe nuclei, hy-
pothalamus, thalamus, and hippocampus and least abundant in
striatum and anterior cortical regions (Fig. 3B). There was a
strong correlation (r 0.943; p 0001) between 5-HTT binding
in brain regions of thewild types versus transgenicmice (Fig. 3C),
indicative of a similar 5-HTT expression pattern across the
genotypes.
Brain tissue levels of 5-HT and 5-HT synthesis
and metabolism
Transgenic mice showed reduced tissue levels (15 to 35%) of
5-HT in the hippocampus, frontal cortex, hypothalamus, brain-
stem, andmidbrain compared with wild-type animals (Fig. 4). In
comparison, levels of the 5-HT metabolite, 5-HIAA, were not
significantly different (Fig. 4).
In separate experiments, accumulation of the 5-HT precursor
5-HTP (after aromatic amino acid decarboxylase inhibition) in
the cortex, striatum, and hippocampuswas not different between
wild-type and transgenic mice (Table 1). These experiments also
confirmed that tissue levels of 5-HT were significantly lower in
transgenic mice than wild types and that 5-HIAA levels were
unchanged (data not shown). Regional levels of the dopamine
metabolite DOPAC and accumulation of the catecholamine pre-
cursor DOPA were not different between transgenic and wild-
type mice (Table 1 and data not shown).
Brain extracellular 5-HT levels
In microdialysis experiments, 5-HTT-overexpressing mice dem-
onstrated constantly lower (50 to 60%) basal extracellular lev-
els of 5-HT in both the prefrontal cortex (effect of genotype;
F(1,9) 5.4; p 0.05) and hippocampus (F(1,8) 13.0; p 0.05)
compared with wild-type mice (Fig. 5A,B). This difference was
stable and maintained over 3–4 h of baseline sampling. Also, in
both regions, the increase in 5-HT evoked by local application
of high potassium (56 mM) was significantly ( p  0.05) less
(40–80%) in the transgenic mice compared with wild types
(Fig. 5A,B).
Separate experiments showed that the low levels of extracellu-
lar 5-HT in the prefrontal cortex of 5-HTT-overexpressing mice
could be reversed by local application of 1 M paroxetine. Thus,
whereas the transgenic mice had 50% lower 5-HT levels than the
wild types (F(1,8)  8.5; p  0.02), after paroxetine 5-HT levels
were not significantly different (Fig. 5C). Also, systemically ad-
ministered paroxetine (5 mg/kg, s.c.) caused a rise in cortical
extracellular 5-HT in transgenic mice that was similar in magni-
tude to that observed inwild-typemice [203.4 65.9% (n 5)
vs235.3 70.5% (n 5) of predrug values at t 60 min after
paroxetine].
Transgenic andwild-typemice did not differ in basal extracel-
lular levels of either dopamine in the prefrontal cortex [0.040
0.006 pmol/40 l (n 5) vs 0.054 0.008 pmol/40 l (n 5)]
and striatum [0.214 0.089 pmol/40l (n 5) vs 0.133 0.046
pmol/40 l (n  5)] or noradrenaline in the prefrontal cortex
[0.1080.020pmol/40l (n5)vs0.0900.012pmol/40l (n
5)] andhippocampus [0.041 0.009pmol/40l (n 5) vs 0.029
0.005 pmol/40l (n 5)].
Figure 2. Detection of 5-HTT expression by in situ hybridization in 5-HTT-overexpressing transgenic (Tg) andwild-type (Wt)mice. 5-HTT expression in the raphe (A,B, F,G), hippocampus (C,H ),
olfactory bulb (D, I ), and piriform cortex (E, J ) of the transgenic (A–E) and wild-type (F–J ) mice using m5-HTT-specific probe (A, F ) and h5-HTT probe (B–E, G–J ).
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Anxiety tests
Elevated plus maze
Drug naive 5-HTT-overexpressing mice
spent significantly more time on the open
arms of the plus maze ( p  0.05) and
showed a shorter latency ( p  0.06) to
first enter the open arm than drug naive
wild-type mice, whereas total arm entries
were not different between genotypes
(Fig. 6A).
Open and closed arm entries by the
transgenicmice (6 1 and 10 1, respec-
tively) were not significantly different
from wild-type mice (4  1 and 11  1).
Similarly, ratios for open/closed and open/
total entries by the transgenicmice (0.65
0.11 and 0.37  0.04, respectively) were
not significantly different from wild-type
mice (0.40  0.14 and 0.24  0.06), sug-
gesting that the decreased latency to enter
the open arms and increased time spent on
the open arms is specifically linked to re-
duced anxiety and not a function of
changes in locomotor activity.
Additional plus maze experiments on a
separate cohort ofmice confirmed that the
transgenic mice spent significantly more
time on the open arms of the plus maze
( p  0.05) and showed a shorter latency
( p 0.05) to first enter the open arm than
wild-typemice (Fig. 7). These experiments
also demonstrated that the low-anxiety
phenotype of the transgenic mice could be
reversed by inhibition of the 5-HTT (Fig.
7). Thus, transgenic mice administered 10
mg/kg paroxetine intraperitoneally spent
significantly less time on the open arm,
and showed a significantly greater latency
to enter the open arms, compared with
transgenic mice administered saline ( p 
0.02) (Fig. 7). In wild-type controls, par-
oxetine (10 mg/kg, i.p.) had no effect on
either the time on the open arm or latency
to enter the open arms (Fig. 7).
Hyponeophagia
In the hyponeophagia test, 5-HTT-
overexpressing mice displayed a signifi-
cantly decreased latency to eat compared
with wild-type mice (Fig. 6B) ( p 0.05).
5-HTT-overexpressing mice showed no
significant difference in the amount of
food consumed overnight compared with
wild types (Fig. 6C).
Open field
5-HTT-overexpressing mice did not show
a difference in the number of squares entered in the open field
compared with wild types (Fig. 6D).
Discussion
A common, naturally occurring polymorphism in the 5-HTT
gene promoter region of the human 5-HTT gene (l/l genotype)
that increases 5-HTT expression has been associated with re-
duced anxiety levels in human volunteers and in patient popula-
tions (see Introduction). The present study investigated the neu-
rochemical and behavioral effects of increased 5-HTT expression
by generating a novel transgenicmousemodel that overexpresses
the h5-HTT from a YAC construct. These data suggest that in-
creased 5-HTT expression produces a low-anxiety phenotype
and that this is mediated by decreased 5-HT transmission.
Figure 3. Autoradiograms showing the distribution (A), quantification (B), and regional correlation (C) of [ 3H]citalopram
(Cital) binding sites in brain sections of 5-HTT-overexpressing (Tg) and wild-type (Wt) mice. Sections were cut at approximately
levels 21–23 (bottom), 46–48 (middle), and 67–69 (top) according to the mouse stereotaxic atlas of Franklin and Paxinos
(1997). The abbreviations for Bwith corresponding numbers for C are as follows: motor, motor cortex (4); Cing, cingulate cortex
(3); Pre/Infra, prelimbic/infralimbic cortex (2); Orbital, orbital cortex (6); Somat, somatosensory cortex (5); Striatum, striatum (1);
Nacc, nucleus accumbens (7); CA1, CA1 (8); CA3, CA3 (9); Hyp, hypothalamus (11); Thal, thalamus (10); DRN, dorsal raphe nucleus
(13); MRN, medial raphe nucleus (12). All determinations in the transgenic mice were statistically significant (*p 0.05, Stu-
dent’s unpaired t test) compared with wild-type controls. Error bars indicate SEM.
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General features of the 5-HTT-overexpressing mice
A selected transgenicmouse line (A102.3) showed the presence of
h5-HTT mRNA in brainstem extracts analyzed by RT-PCR, and
in situ hybridization studies demonstrated the increased abun-
dance of 5-HTTmRNA in the midbrain raphe nuclei. The trans-
genic mice also had increased 5-HTT protein expression across a
range of forebrain and midbrain regions, as determined by auto-
radiographic measurement of 5-HTT binding sites using the se-
lective 5-HTT radioligand [3H]citalopram. Although the num-
ber of 5-HTT binding sites increased in transgenic animals, the
pattern of expression showed a close correlation with that seen in
wild-type mice and corresponded with that seen in other studies
using [3H]citalopram and similarly selective 5-HTT radioligands
such as 3H-paroxetine (De Souza and Kuyatt, 1987; Le Marec et
al., 1998). It is possible that differences in distribution of 5-HTT
between these studies and other reports (Bengel et al., 1997) re-
lates to differences in selectivity of the radioligands used.
An interesting feature of the transgenic mouse is that the level
of 5-HTT expression (mRNA and binding sites) was twofold to
threefold greater than wild-type mice. A similar degree of varia-
tion in 5-HTT binding sites is reported in healthy individuals in
postmortem and neuroimaging studies (Malison et al., 1998;
Mann et al., 2000). Naturally occurring variation in 5-HTT ex-
pression may, at least in part, be genetically driven because indi-
viduals with the l/l genotype show about a twofold increase in
5-HTuptake, 5-HTTbinding sites, andmRNA in studies of brain
and platelets compared with individuals with the s/s and s/l geno-
types (Hanna et al., 1998; Little et al., 1998; Greenberg et al., 1999;
Heinz et al., 2000).
In addition to showing increased abundance of 5-HTTmRNA
in the midbrain raphe nuclei, the transgenic mice also had trace
amounts of 5-HTTmRNA in the forebrain. Although the present
study did not detect extra raphe 5-HTTmRNA inwild-typemice,
this finding was not entirely unex-
pected, because low levels of 5-HTT
mRNA have been reported previously
in rat cortex and hippocampus (Lesch
et al., 1993) and in human cortex
(Hernandez and Sokolov, 1997; Sun
et al., 2001) using sensitive PCR-
basedmethods. It has been speculated
previously that the low levels of
Table 1. 5-HTP and L-DOPA accumulation in brain regions of 5-HTT-overexpressing transgenic (Tg) and wild-type (Wt)
mice
Frontal cortex Striatum Hippocampus
Wt Tg Wt Tg Wt Tg
5-HTP (pmol/mg) 0.83 0.038 0.79 0.053 1.1 0.051 1.1 0.093 2.5  0.37 2.1  0.30
L-DOPA (pmol/mg) 0.84 0.074 0.94 0.085 3.8 0.17 3.7 0.34 0.79 0.14 0.58 0.092
Mice (n10per group)were administered the aromatic amino acid decarboxylase inhibitor NSD1015 (100mg/kg) 30minbefore tissue removal. The data shownare
mean SEM values.
Figure 4. Tissue levels of 5-HT (A) and 5-HIAA (B) in brain regions of 5-HTT-overexpressing
(Tg) andwild-type (Wt)mice. Ctx, Cortex; Bs, brainstem;Mb,midbrain; Hip, hippocampus; Hyp,
hypothalamus.Mean SEM(n8) values are shown. *p0.05,wild-type versus transgenic
mice (Student’s unpaired t test).
Figure 5. Levels of 5-HT in microdialysates from anesthetized 5-HTT-overexpressing (Tg)
and wild-type (Wt) mice. A, Basal and potassium-evoked 5-HT in the medial prefrontal cortex.
B, Basal andpotassium-evoked 5-HT in the hippocampus. C, Basal 5-HT in themedial prefrontal
cortex and effect of locally applied paroxetine. High potassium (56mM) and paroxetine (1M)
were added to the perfusion medium as indicated by the bars. Mean SEM values are shown
(n 5–6 per group).
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5-HTTmRNA in the forebrainmight arise through trafficking to
the 5-HT nerve terminals (Lesch et al., 1993). Also, expression of
5-HTT protein in non-5-HT neurons has been detected in the
limbic brain regions (Pickel and Chan, 1999). Nevertheless, the
presence of 5-HTTmRNA in the forebrain of the transgenicmice
may be evidence of a low level of 5-HTT expression in atypical
sites. Although the present study did notmeasure 5-HTT expres-
sion in peripheral tissues of the 5-HTT-overexpressing mice, a
recent paper reported increased 5-HTT immunoreactivity and
binding sites in the lungs of these animals (MacLean et al., 2004).
Neurochemical changes in the 5-HTT-overexpressing mice
The 5-HTT-overexpressingmice demonstrated a robust and spe-
cific neurochemical phenotype in terms of decreased extracellu-
lar 5-HT as well as decreased whole tissue levels of 5-HT in dif-
ferent brain regions. In in vivo microdialysis experiments, basal
extracellular levels of 5-HT in mPFC and hippocampus in the
transgenic mice were lower (50%) than wild types, and the 5-HT
response to a depolarizing stimulus of high potassiumwas signif-
icantly reduced. Importantly, extracellular 5-HT in the trans-
genic mice increased toward wild-type levels in response to ad-
ministration of the 5-HTT inhibitor paroxetine. This observation
suggests that an increased 5-HTT activity contributes to the low
extracellular levels of 5-HT observed in the transgenic mice.
Interestingly, the transgenic mice had low whole-tissue levels
of 5-HT (35 to 60% of wild types) across a range of brain
regions examined. Therefore, it is likely that less 5-HT is available
for release, and this may also contribute to the low extracellular
levels that these animals demonstrate. The origin of the decreased
5-HT tissue content is uncertain because levels of both metabo-
lism (5-HIAA) and 5-HT synthesis (5-HTP accumulation) were
unchanged. However, because the major contributor to whole-
tissue 5-HT levels is likely to be the vesicular storage compart-
ment, the transgenic mice may have a 5-HT storage deficit. This
notion would be consistent with studies showing that 5-HT stor-
age depletion by inhibition of vesicular monoamine uptake
(VMAT2) with reserpine results in reduction in both tissue and
extracellular 5-HT levels in the brain, without changed 5-HT
metabolism (Heslop and Curzon, 1994; Hatip-Al-Khatib et al.,
2001). The 5-HTT-overexpressing mice do not show evidence of
altered VMAT2 mRNA expression (our unpublished observa-
tion), but another possible source of a 5-HT storage deficit could
be disrupted interactions between the 5-HTT and proteins in-
volved in vesicle formation and utilization (Rothman, 1996;
Bajjalieh, 2001; Kavalali, 2002; Quick, 2002, 2003).
Behavioral changes in the 5-HTT-overexpressing mice
Compared with wild-type mice, the 5-HTT-overexpressing mice
showed evidence of decreased anxiety-like behavior in two ani-
mal models of anxiety. On the elevated plus maze test, the trans-
genic mice were quicker to enter the open arms and spent more
time on these arms, and in the hyponeophagia test, the mice
showed a decreased latency to eat. The findings in both models
have been confirmed using a separate colony of animals (Figs. 6,
7, and our unpublished data). It is unlikely that reduced anxiety-
like behavior has come about as a result of altered locomotion or
feeding activity as the two tests place distinct sensorimotor and
motivational demands on the animal. Moreover, in a battery of
behavioral tests of exploratory function andmotor coordination,
as well as daily food and water consumption, the transgenic mice
were not different from wild-type controls (see Results and our
unpublished data).
In the plus maze test, administration of paroxetine increased
anxiety levels of the transgenic mice such that the mice were not
distinguishable from wild-type controls. Paroxetine was without
significant effect on the plus maze performance of the wild-type
mice. These results have two implications. First, the results sug-
gest that the low-anxiety phenotype of the transgenic mice is
driven by an ongoing overexpression of the 5-HTT. Although
recent findings suggest that the changes in anxiety observed in
5-HT1A receptor null mutant mice are developmental in origin
(Gross and Hen, 2004), this appears not to be the case for the
changes in anxiety observed in the 5-HTT-overexpressing mice.
Second, the results with paroxetine suggest that the low-
anxiety phenotype of the 5-HTT-overexpressingmice is linked to
the decrease in presynaptic 5-HT function observed in the neu-
rochemical experiments. This idea is strengthened by evidence
from microdialysis experiments that paroxetine caused a rise in
Figure 6. Behavioral measures of anxiety in 5-HTT-overexpressing (Tg) and wild-type (Wt)
mice.A, Latency to enter open arms, time on open arms, and total number of arm entries in the
elevated plus maze (left to right). B, Latency to eat in hyponeophagia test. C, Overnight food
consumption.D, Activity in the open-field test. The data shown aremean SEM values. *p
0.05 transgenic versus wild-type mice (Student’s unpaired t test).
Figure 7. Behavioral measures of anxiety in 5-HTT-overexpressing (Tg) and wild-type (Wt)
mice treated with the 5-HTT inhibitor paroxetine (Parox) or saline vehicle. Paroxetine (10 mg/
kg, i.p.) was administered 30 min before testing. The data shown are mean SEM values.
*p 0.05 transgenic versus wild-type mice; #p 0.05, paroxetine versus saline (Student’s
unpaired t test).
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extracellular 5-HT in the transgenic mice. Moreover, there is
much previous evidence associating drug-induced reductions in
5-HT function with decreased anxiety in a range of animal mod-
els (Griebel, 1995; Handley, 1995). In particular, 5-HT depletion
by 5-HT synthesis inhibition or 5-HT lesions is reported to lower
anxiety in the plus maze test (Briley et al., 1990; Soderpalm and
Engel, 1990; Critchley et al., 1992).
Comparison of 5-HTT-overexpressing and 5-HTT
knock-out mice
The neurochemical and behavioral phenotypes of the 5-HTT-
overexpressing mice reported here are essentially opposite to
those reported in 5-HTT null mutant mice. Thus, in microdialy-
sis experiments, homozygous 5-HTT knock-out mice demon-
strate raised extracellular 5-HT in various brain regions (Fabre et
al., 2000; Shen et al., 2004), and in the elevated plus maze and
hyponeophagia models, these animals exhibit high levels of anx-
iety (Holmes et al., 2003a,b; Lira et al., 2003).
These observations reinforce the argument that there is a
causal relationship between altered 5-HT function and behav-
ioral changes in bothmodels.Moreover, these results suggest that
variation in 5-HTT expression over a wide range may lead to
proportionate changes in 5-HT function and anxiety-related be-
haviors. Thus, despite themanymechanisms thatmight compen-
sate for the effects of 5-HTT gene variation, this single gene ap-
pears to be a strong determinant of anxiety-related behavior.
Curiously, as with 5-HTT knock-out mice (Kim et al., 2005),
5-HTT-overexpressing mice have reduced whole-tissue levels of
5-HT. It is plausible that this reflects a common underlying
mechanism such as disruption in 5-HT storagemechanisms, pos-
sibly through altered interactions between the 5-HTT and pro-
teins involved in vesicular formation and trafficking (Bengel et
al., 1998; Kim et al., 2005).
In summary, 5-HTT-overexpressing mice demonstrate re-
duced presynaptic 5-HT function and low-anxiety-like behavior,
and our data indicate that these neurochemical and behavioral
phenotypes are linked. We propose that associations between
increased 5-HTT expression and anxiety can be modeled in mice
and may be specifically mediated by decreases in 5-HT
transmission.
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